Mr. President, I rise today to address a serious and deadly health issue. I am talking about tobacco, a scourge on our society. Smoking kills. There is no such thing as a safe cigarette. These are…
Mr. President, I rise today to address a serious and deadly health issue. I am talking about tobacco, a scourge on our society.
Smoking kills. There is no such thing as a safe cigarette. These are not mere platitudes. They are the deadly truth. Tobacco kills more Americans each year than alcohol, cocaine, crack, heroin, homicide, suicide, car accidents, fire and AIDS combined.
My colleague Senator Kennedy has proposed dealing with this shocking statistic by having the Food and Drug Administration regulate tobacco. I suggest my colleagues ask themselves: What will it mean to have cigarette and tobacco products regulated by the FDA?
The FDA is the gold standard among public health regulators the world over. For the past century, the FDA has protected the public, from filthy conditions in meat packing plants to thalidomide, which caused thousands of birth defects in Western Europe. The FDA's constant vigilance is not just an historical artifact. It seems like every day there is something new for the FDA to protect us from. The headlines behind me show how we have come to depend on the FDA every day to protect us and our children from poisons that could harm or even kill us.
It is evident that the FDA is overworked and underfunded. We, as a nation, currently ask the FDA to be responsible for so many things: ensuring that new drugs and medical devices are safe and effective; safeguarding the Nation's food supply; regulating the manufacture and distribution of food additives and drugs that will be given to animals; and, increasing the security of our blood supply.
In each of these key activities, the role of the FDA is to protect our health. In providing that protection, the FDA examines key scientific facts and weighs the balance of benefit to our society and risk to our health. It is incomprehensible to me to extend that critical role to an FDA risk/benefit analysis of tobacco and cigarettes.
I will say it again: Smoking kills. There is no such thing as a ``safe'' cigarette. Any public statement by the FDA under their current authority would necessitate the finding that there is no benefit to the use of cigarettes, only harm.
The Kennedy-Cornyn bill would establish the FDA as the regulator for tobacco products. However, the bill explicitly states that the FDA will not be permitted to prohibit the sale of any tobacco product to adults. That is not true regulation. The bill would gut the authority that Congress has bestowed and staunchly defended for the FDA, the authority to remove health threats from the marketplace. This approach is so flawed that I believe the bill cannot be fixed.
Even having the FDA review and approve cigarettes sends mixed and confusing messages to the public, creating the sense that cigarettes are safe or can be made safer. The FDA cannot be put in the position of approving a product which years of science and the personal experience of far too many Americans has shown to be dangerous. Simply put, tobacco kills people. Piling on regulations and bureaucracy won't change that.
I commend my colleague Senator Kennedy for trying to do something about the evil of tobacco. But this bill is a dinosaur. It has been introduced year after year, with barely any changes. In fact, the bill would have FDA issue a regulation from 1996 completely intact. A regulation, I might add, that was overturned by the Supreme Court. But that is beside the point. Instead of resurrecting broken, outdated legislation, we should be aiming to make tobacco extinct.
While some in the tobacco industry claim to share my views on smoking, I do not believe they have actually bought in to the idea of getting people to stop using tobacco. A case in point is the new $350 million facility Philip Morris has built in Richmond, VA. I ask unanimous consent to have printed in the Record the following classified ad from the journal Science.
Mr. President, this ad calls for the recruitment of scientists to work at this facility, studying how to ``develop relevant exposure models'' for smoking related diseases. Or to do large scale epidemiology studies on ``the cause of cigarette smoke-related diseases.'' Here I thought the cause of cigarette smoke-related diseases was smoking. Silly me.
Clearly, Philip Morris believes it will still be able to operate under the Kennedy bill. It will be business as usual for the Marlboro Man, and more Americans will die needlessly.
Trying to make cigarettes safer through a billion-dollar bureaucracy is a waste of time and money. The right approach is to get people to stop smoking, or better yet, to never start.
The key failing of the Kennedy dinosaur legislation is that it will not reduce smoking. In 2004, this bill did pass the Senate, as part of FSC-ETI. The Congressional Budget Office, in scoring the Senate-passed bill, examined the tobacco provisions. I suggest my colleagues study that score carefully. CBO suggested there would be essentially no reduction in adult smoking, and only a 12.5 percent reduction in youth smoking. The bill assesses user fees in excess of $450 million a year. There are currently 2.7 million youth smokers. When you do the math, it comes out to nearly $1,500 per year per youth smoker to achieve these reductions. I don't know if you've talked to any teenagers recently, but they are pretty entrepreneurial. I bet a lot of them would quit smoking if you just paid them to give it up, or even to stay off the stuff in the first place.
In another example of very little bang for very big bucks, a recent Institute of Medicine report from May says that if we keep doing what we are doing, we will reduce smoking from the current 20 percent of the population to about 15 percent over the next 20 years. If we do everything in the report, which is basically the Kennedy bill plus a number of other steps, some of which maybe unconstitutional, we might reduce it to 10 percent. At an unknown, but likely very high, cost.
This bill can't be fixed. I know we can do better. We just have to think bigger. We must win the war on tobacco, not sign a peace treaty with Phillip Morris.
I have developed my own tobacco legislation that would truly have an impact on the number of smokers in this country, and I am pleased to introduce today the Help End Addiction to Lethal Tobacco Habits or HEALTH Act.
My bill contains a novel cap-and-trade program--guaranteeing that
fewer people suffer the deadly consequences of smoking, while providing flexibility in how those reductions are achieved.
Cap-and-trade programs have a proven track record in the environmental arena. In the 1980s, lakes and forests were dying from acid rain. The acid rain was caused by emissions of sulfur and nitrogen oxides from power generation at electrical plants. The Clean Air Act amendments of 1990 instituted a system of allowances for emissions of sulfur and nitrogen oxides that could be used, banked, traded or sold freely on the open market. The number of allowances decreased each year. This system achieved the desired results faster and at lower cost than had been anticipated. The cap-and-trade program for sulfur and nitrogen oxides has made dramatic differences in our air quality over the past 15 years, and is a resounding success. I propose to carry this market-oriented system over to the tobacco control arena. Although this has never been tried for a health issue, I think it will work.
My legislation will contain a cap-and-trade system for shrinking the size of the tobacco market over the next 20 years. Smoking reductions are guaranteed, and companies are given time and flexibility to make the reductions or divest. In addition, small tobacco companies would have a valuable asset in their allocations, leveling the playing field a bit between the smaller and larger industry members. Finally, and I think very importantly, public health groups could buy and retire allowances to achieve the reductions in tobacco use even faster than specified in my bill. I would like to issue a challenge today to those groups, use your clout to help me make this work. Stand with me to fight tobacco and protect the health of all Americans.
I want to remind my colleagues that the FDA approves cures, not poisons. Forcing the FDA to regulate tobacco but not letting them ban it, as my colleague Senator Kennedy proposes, would undermine the long history of the agency protecting and promoting the public health.
In closing, every day, we hear about some new problem the FDA faces in protecting our health. From contaminated seafood to tainted toothpaste, this agency is in dire need of congressional support to carry out its mission. We should be focusing our efforts on increasing the number of inspectors, and on renewing the expiring drug and device user fee laws.
I ask my colleagues to think hard about what they are proposing when they suggest FDA regulation is the way to defeat tobacco. My record is clear when it comes to tobacco. I am no friend of big tobacco and I have never taken a dime of tobacco company money for my campaigns. I don't intend to start now. But I absolutely reject the notion that the way to show you're ``for kids'' and ``against Big Tobacco'' is by sending the Nation's premier public health watchdog out to fight for safety with one hand tied behind its back. We must not mandate the FDA seal of approval on a deadly product that has no health benefit whatsoever. We can do better. Will you join me?
Health Science Research for Harm Reduction--New Positions at Philip
Morris USA
The Health Sciences Research Division of PM USA is seeking
Leading Scientists in several biomedical-related research
areas.
The primary goal of the Health Sciences Research Division
(HSR) is to conduct health science research to facilitate the
development of new methods and technologies with the
potential to reduce harm associated with our products.
In June 2007, PM USA research scientists will begin
occupying the new 450,000 sq. ft., state-of-the-art Center
for Research and Technology (CRT) facility. HSR scientists
will work in collaboration with other PM USA scientists at
the CRT to investigate and discover technologies for the
reduction of harm associated with our products.
Cigarette Smoke-Related Disease Scientists: Will
participate in the development of models and biomarkers of
cigarette smoke-related diseases including: Cancer Scientists
investigating cancer with emphasis on lung cancer. COPD
Scientists investigating chronic obstructive pulmonary
disease. CVD Scientists investigating cardiovascular disease.
Experimental Pathologists: Will participate in the
development and use of microscopic and imaging techniques to
investigate the cause of cigarette smoke-related diseases.
Oxidative Stress Scientists: Will participate in studies
investigating the role of oxidative damage and cell death
processes in cigarette smoke-related diseases.
Inflammation/Immune System Scientists: Will participate in
studies investigating the role of inflammatory/immunological
processes in cigarette smoke-related diseases.
Inhalation Toxicologist for Aerosol Dosimetry: Will
participate in studies investigating in vitro and in vivo
exposure to cigarette smoke to quantify airway smoke
deposition and develop relevant exposure models.
Toxicologist for PK-PD Studies: Will study the PK-PD of
exposure to cigarette smoke during smoke inhalation for the
purpose of developing clinically predictive cell and tissue
dose models.
Epidemiologists (Molecular/Genetic and Chronic Disease):
Will participate in the design, conduct and analysis of
large-scale, high-throughput, molecular and chronic disease
epidemiologic studies on the cause of cigarette smoke-related
diseases (CVD, COPD, Cancer).
Biostatisticians: Will participate in the design and
analysis of large-scale epidemiologic, in vitro and in vivo
studies on the cause of cigarette smoke-related diseases
(CVD, COPD, Cancer).
Geneticists (Statistical and Population): Will participate
in the design and analysis of large-scale, high-throughput,
molecular epidemiologic and in vivo studies on cigarette
smoke-related diseases (CVD, COPD, Cancer).
Complex Systems Analysts (Systems Biology): Will
participate in the integration and modeling of high-
throughput, cross-platform, trans-species data on cigarette
smoke-related diseases (CVD, COPD, Cancer).